Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

58.03 +5.95 (+11.42%)
Streaming Delayed Price Updated: 10:50 AM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
36 37 Next >
News headline image
2 Nasdaq Growth Stocks That Are Screaming Buys in April ↗
Massive drivers of fresh earnings are drawing closer, and risks are declining. 
Via The Motley Fool
News headline image
These Up-and-Coming Stocks Are Screaming Buys Right Now ↗
Both companies could deliver revenue and share price growth over the long term. 
Via The Motley Fool
News headline image
Could This Move Make Vertex's Next Blockbuster Even Bigger? ↗
Vertex is showing it can branch out beyond its cystic fibrosis specialty. 
Via The Motley Fool
News headline image
Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity? ↗
The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.  
Via Benzinga
News headline image
Where Will CRISPR Therapeutics Be in 5 Years? ↗
Could CRISPR Therapeutics be the next big healthcare stock? 
Via The Motley Fool
News headline image
CRISPR Stock: Bull vs. Bear ↗
CRISPR's first approved product may be right around the corner. 
Via The Motley Fool
News headline image
Why Bluebird Bio Shares Are Plunging Today ↗
 
Via Benzinga
News headline image
Could This Stock Become the Tesla of Its Industry? ↗
It's in a race to a multi-billion dollar market. 
Via The Motley Fool
News headline image
Expert Ratings for CRISPR Therapeutics ↗
 
Via Benzinga
News headline image
5 S&P 500 Stocks Showing Strength As Recession Fears Rise ↗
Medical stocks are holding up amid economic and market uncertainty. 
Via Investor's Business Daily
News headline image
What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio ↗
Both biotechs are aiming for the same markets, but they are not equally risky. 
Via The Motley Fool
News headline image
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio ↗
Neither stock is a good choice for those who can't handle a lot of risk. 
Via The Motley Fool
News headline image
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global ↗
 
Via Benzinga
News headline image
2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗
Both companies have game-changing product portfolios that should result in stock price growth. 
Via The Motley Fool
News headline image
Vertex Is 1 Step Closer to Bringing a New Blockbuster to Market. Time to Buy? ↗
Vertex shares are on the rise. 
Via The Motley Fool
News headline image
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
The 10 Best Stocks to Buy in April 2023 ↗
Here are 10 stocks to buy now that could unlock explosive gains in your growth-stock portfolio. 
Via The Motley Fool
News headline image
Here's a New Million-Dollar Reason to Buy CRISPR Therapeutics ↗
Together, the companies could produce a game-changing product. 
Via The Motley Fool
News headline image
5 Bargain-Basement Stocks to Buy Right Now ↗
Down markets offer us something very positive: deals on quality companies. 
Via The Motley Fool
News headline image
The 3 Best Growth Stocks to Buy in the Biotech Sector ↗
These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors. 
Via InvestorPlace
News headline image
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures ↗
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
Via InvestorPlace
News headline image
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Could CRISPR Therapeutics Become the Next Moderna? ↗
Both companies use cutting-edge technology. 
Via The Motley Fool
News headline image
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket ↗
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
News headline image
3 Simple Ways to Supercharge Your Biopharma Investing Using Artificial Intelligence ↗
Your stock screening and research process will never be the same. 
Via The Motley Fool
News headline image
This Cathie Wood Stock Could Nearly Double, According to Wall Street ↗
If the stock market continues to rally, this biotech could benefit. 
Via The Motley Fool
News headline image
Thinking of Buying Biotech Stocks? Do These 3 Things First ↗
It's better to plan ahead than to get caught by surprise. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 ↗
 
Via Benzinga
News headline image
3 Cutting-Edge Healthcare Stocks That Can Pay Off Big Time ↗
For investors betting on healthcare, look for these three companies to provide the treatments of tomorrow. 
Via InvestorPlace
News headline image
3 Beaten-Down Stocks That Could Soar This Year ↗
These stocks could enjoy big rebounds in 2023. 
Via The Motley Fool
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.